Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial.
Berta TorresA C GuardoM SquarciaA DiazA FabraM CaballeroA UgarteL LealJ M GatellM PlanaFelipe GarciaPublished in: HIV medicine (2021)
Losartan had no effect on lymphoid fibrosis or immune activation/inflammation. Conversely, switching to a regimen with raltegravir significantly decreased activated and senescent T-lymphocyte subpopulations and increased CD4/CD8 ratio in successfully treated PLWH.